ADAM17-IN-1
ADAM17-IN-1 is a selective inhibitor of ADAM17. ADAM17-IN-1 inhibits ADAM17 activity to reduce metabolic activity of dendritic cells (DCs), impair DC antigen-presenting function, suppress allergen-specific Th2 cell polarization, and reduce Th2 cytokine (IL-4, IL-5, IL-13) secretion. ADAM17-IN-1 demonstrates protective efficacy against house dust mite (HDM)-induced type 2/eosinophilic airway inflammation in mice. ADAM17-IN-1 can be used for the study of type 2-high allergic asthma.
For research use only. We do not sell to patients.
- CAS No.: 1802395-34-1
- Formula: C40H55N5O4
- Molecular Weight:669.90
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
ADAM17 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| THP-1 | IC50 |
28 μM
Compound: 19
|
Inhibition of ADAM17 in human THP1 cells assessed as inhibition of LPS-stimulated TNFalpha cleavage after 1 hr by AlphaScreen assay
Inhibition of ADAM17 in human THP1 cells assessed as inhibition of LPS-stimulated TNFalpha cleavage after 1 hr by AlphaScreen assay
|
[PMID: 26192023] |
In Vitro
ADAM17-IN-1 (Compound 2155-17) (50 μM) significantly reduces the oxygen consumption rate (OCR) and spare respiratory capacity (SRC) of BMDCs, inhibits mitochondrial oxidative phosphorylation, and impairs DC metabolic activity[1].
ADAM17-IN-1 (50 μM, pre-treated HDM-pulsed BMDCs followed by 4-day co-culture with CFSE-labeled CD4+T cells from OTII mice) significantly decreases OVA323-339 peptide-specific T cell proliferation rate, reduces Th2 cytokine (IL-13) secretion and the proportion of CD4+GATA3+Th2 cells[1].
ADAM17-IN-1 (0.316-3.16 μM, treated on mouse oligodendrocyte progenitor cells (OPCs)) promotes OPC differentiation in a dose-dependent manner without inducing cell apoptosis, showing no obvious cytotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
ADAM17-IN-1 (200 μg/mouse, intranasal administration, Days 8, 10, 12, 14 concurrent with HDM challenge) significantly reduces total inflammatory cells and eosinophils in BAL/lung[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HDM-induced allergic asthma model in WT mice (C57BL/6, 6-10 weeks old) with adoptive transfer of BMDCs[1]
-
Dosage:50 μM in vitro pre-treatment for 16 h
-
Administration:Adoptive transfer of 0.75×105 CD11c+ BMDCs via i.n. on Day 0, followed by i.n. HDM challenge (50 μg/mouse) on Days 9, 11, 13, 15
-
Result:Exhibited decreased number of total BAL cells and eosinophils.
Reduced BAL CCL24 levels and serum HDM-specific IgG1/IgE levels.
Declined IL4, IL5, and IL13 production in DLn cells.
Alleviated peribronchial inflammatory cell infiltrates and mucous cell metaplasia in lung.
-
Animal Model:HDM-induced allergic asthma model in WT mice (C57BL/6, 6-10 weeks old) with adoptive transfer of BMDCs[1]
-
Dosage:200 μg/mouse
-
Administration:i.n., Days 8, 10, 12, 14 concurrent with HDM challenge
-
Result:Reduced total inflammatory cells and eosinophils in BAL and lung.
Decreased serum HDM-specific IgG1/IgE levels and lung IL5/IL13 levels.
Reduced peribronchial inflammatory cell infiltrates and mucous cell metaplasia in lung.
Chemical Information
-
CAS No. 1802395-34-1
-
Molecular Weight 669.90
-
Formula C40H55N5O4
-
SMILES
CCC[C@@H](CNC(C1=O)=O)N1C[C@H](CCC2)N2C[C@H](N3C[C@@H](N(C(C3=O)=O)CCC4=CC=CC=C4)CC5=CC=CC=C5)CC6CCCCC6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Ovalbumin-Induced Allergic Airway Inflammation
Ovalbumin-induced allergic airway inflammation is a mouse model in which systemic sensitization to ovalbumin, usually with aluminum hydroxide adjuvant, is followed by airway ovalbumin challenge to induce allergic airway inflammation, eosinophil recruitment, mucus production, serum antigen-specific IgE, Th2 cytokine responses, and airway hyperresponsiveness to methacholine. The model is used to study allergen-driven airway inflammation and asthma-like immune responses, but it does not reproduce every feature of human asthma. The main readouts are bronchoalveolar lavage fluid cellularity, lung histopathology, airway hyperresponsiveness, serum OVA-specific IgE, and cytokines such as IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid or lung samples. Eosinophilia and Th2 cytokines reflect allergic type 2 inflammation, while methacholine responsiveness provides a functional airway-reactivity endpoint.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)